Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy

Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02500225

Enrollment

Registered

2015-07-16

Start date

2017-01-31

Completion date

2017-02-28

Last updated

2019-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, ECT

Keywords

Etomidate, Sevoflurane

Brief summary

The purpose of the study was to investigate the effects of etomidate or sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles.

Detailed description

Twenty-five patients will be a total of 150 ECT treatments in this prospective, double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group 1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of consciousness for their initial electroconvulsive therapy session. In subsequent sessions, patients will receive the alternative sevoflurane concentration and then alternated between doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine. Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean arterial pressure (MAP) values, and recovery times will recorde.

Interventions

DRUGEtomidate

0.2 mg/kg etomidate

DRUGSevoflurane

8% Sevoflurane

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Study include 25 patients of American Society of Anesthesiologists (ASA) physical status I-II aged between 18-60 years who schedule for ECT sessions under general anesthesia

Exclusion criteria

* Pregnancy * Cerebrovascular disease * Epilepsy * Unstable cardiovascular disease * Chronic obstructive pulmonary disease; and * Renal or hepatic failure

Design outcomes

Primary

Measure	Time frame	Description
Motor (EMG) seizure duration	intraoperative	Motor seizure duration in electroconvulsive therapy
electroencephalography (EEG) seizure duration	intraoperative	seizure duration in electroconvulsive therapy

Secondary

Measure	Time frame	Description
heart rate (HR),	(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes	heart rate in electroconvulsive therapy
mean arterial pressure (MAP)	(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes	MAP will be measured by a blood pressure cuff
recovery times	(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes	Recovery times will be assessed with spontaneous breathing, eye opening, obeying commands times

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026